Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 20/20 | 0.63 |
| ▸ | HTR1D | P28221 | 11/20 | 0.60 |
| ▸ | HTR1B | P28222 | 11/20 | 0.60 |
| ▸ | HTR1A | P08908 | 11/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | HTR1E | P28566 | 2/20 | 0.57 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7011169 | 1.00 | HTR1F (0.63) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL30908810 | 0.82 | HTR1F (0.69) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7009114 | 0.82 | HTR1F (0.69) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7004976 | 0.80 | HTR1F (0.81) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL30909108 | 0.80 | HTR1F (0.81) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7011890 | 0.79 | HTR1F (0.58) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL30909281 | 0.79 | HTR1F (0.58) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7485415 | 0.79 | HTR1D (0.60) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL7009531 | 0.79 | HTR1F (0.76) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7009894 | 0.79 | HTR1F (0.69) | HTR1FHTR1DHTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |